8-K filings and company releases
Company news
2 articles on Viking Therapeutics.
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
VKTX articles
Newest first, 25 to a page- Company release
Nov 15, 2026 · Company release
Viking Therapeutics shares VK2735 obesity trial analysis at ObesityWeek 2026
In an exploratory analysis of its Phase 2 VENTURE trial, 74% of participants on weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, versus 15% on placebo.
- Company release
Nov 9, 2026 · Company release
Viking Therapeutics to present two VK2735 posters at ObesityWeek 2026
The posters cover baseline characteristics from the Phase 3 VANQUISH-2 trial and the effects of VK2735 in the Phase 2 VENTURE study.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.
